The tax dispute centres on Piramal Enterprises’ ₹4,487 crore slump sale of its pharma business to Piramal Pharma Limited in FY21, which included the transfer of subsidiary companies. Shares of Piramal Enterprises Ltd ended at ₹872.70, down by ₹31.70, or 3.51%, on the BSE.
